Analyst Price Targets — SEPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 1, 2026 10:35 am | — | Guggenheim | $45.00 | $33.49 | StreetInsider | Septerna Inc (SEPN) PT Lowered to $45 at GuggenheimMember Login |
| July 1, 2026 8:37 am | — | Truist Financial | $43.00 | $33.49 | StreetInsider | Septerna Inc (SEPN) PT Raised to $43 at Truist SecuritiesMember Login |
| June 11, 2026 10:15 am | — | Guggenheim | $52.00 | $30.47 | TheFly | Septerna initiated with a Buy at Guggenheim |
| June 8, 2026 10:32 am | — | Raymond James | $53.00 | $31.15 | TheFly | Septerna price target raised to $53 from $47 at Raymond James |
| March 10, 2026 1:24 pm | Josh Schimmer | Cantor Fitzgerald | $60.00 | $28.06 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN) |
| January 20, 2026 11:19 am | — | H.C. Wainwright | $35.00 | $26.07 | TheFly | Septerna price target raised to $35 from $30 at H.C. Wainwright |
| December 19, 2025 11:28 am | Martin Auster | Raymond James | $38.00 | $27.54 | TheFly | Septerna initiated with a Strong Buy at Raymond James |
| December 15, 2025 11:08 am | — | Truist Financial | $34.00 | $25.47 | TheFly | Septerna initiated with a Buy at Truist |
| November 14, 2025 10:13 am | Derek Archila | Wells Fargo | $28.00 | $19.24 | TheFly | Septerna upgraded to Overweight from Equal Weight at Wells Fargo |
| May 16, 2025 10:15 am | Derek Archila | Wells Fargo | $18.00 | $9.84 | TheFly | Septerna price target raised to $18 from $11 at Wells Fargo |
Latest News for SEPN
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale.
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The…
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SEPN.
U.S. House Trading
No House trades found for SEPN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.